About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 4NCT03183024

Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody

Study to determine the efficacy of benralizumab when compared to placebo in patients with chronic hives that do not respond to antihistamine treatment

Lead sponsor: Jonathan A. Bernstein, MD•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Jonathan A. Bernstein, MD

Subjects with chronic hives that do not respond to antihistamine treatment and have hives of unknown cause will be eligible. Subjects who meet the inclusion/exclusion criteria after the run-in phase will receive 3 doses of study medication. The study also involved blood draws and a punch biopsy of a hive

Age

19 - 70 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•hives for over 6 weeks of unknown cause hives most days of the despite use of antihistamines

Exclusion Criteria

•hives due to known reasons history of cancer pregnant or nursing History of HIV or Hepatitis recent parasitic infection currently or have received treatment with a monoclonal antibody

Related studies

Not Yet RecruitingPhase 3

Autologous Whole Blood Therapy in Chronic Idiopathic Urticaria Patients.

NCT07486583 · Chronic Idiopathic Urticaria

COMPLETEDPhase 2

Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria

NCT05936567 · Urticaria, Chronic Spontaneous Urticaria, and more

COMPLETEDPhase 2

A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases

NCT03858634 · Chronic Idiopathic Urticaria, Chronic Idiopathic Pruritus, and more

COMPLETEDPhase 3

Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria

NCT05774639 · Chronic Idiopathic Urticaria

COMPLETEDPhase 2

Efficacy and Safety of Chemoattractant Receptor-homologous Molecule Expressed on T Helper Type 2 (CRTh2) Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines

NCT02031679 · Chronic Idiopathic Urticaria

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 10, 2019Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE4

Enrollment12

Start dateSep 2017

Last updatedJul 10, 2019

Condition

Chronic Idiopathic Urticaria

Locations shown

Bernstein Clinical Research Center

Cincinnati, Ohio

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 10, 2019Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions